Physician profile
John J Ehum
NPI 1942483409
$3,806.08
in general payments reported to CMS, 2019-2025
25 companies · $661 in 2025
The $661 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $244 · 2021: $746 · 2022: $853 · 2023: $579 · 2024: $435 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,005.80 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.75 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $333.76 | 2020-2025 | Evenity, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $291.47 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $241.01 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $190.70 | 2021-2023 | |
| Novo Nordisk INC | $165.48 | 2022-2025 | Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.49 | 2019 | |
| Vivus LLC | $126.49 | 2021-2023 | Qsymia |
| Abbott Laboratories | $94.80 | 2025 | Id Now Instrument, Freestyle Libre 3 |
| Ibsa Pharma INC. | $88.29 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $87.32 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $86.07 | 2021-2024 | M-M-R II, Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $84.47 | 2022-2024 | |
| Optos, INC. | $80.82 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $77.76 | 2023-2024 | Shingrix, Arexvy |
| Lilly USA, LLC | $41.88 | 2023-2025 | Mounjaro, Emgality, Jardiance |
| Amarin Pharma, INC. | $37.92 | 2021 | |
| Pfizer INC. | $36.07 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $34.01 | 2023-2024 | Farxiga |
| Phathom Pharmaceuticals, INC. | $29.89 | 2024 | Voquezna |
| Corium, LLC | $24.77 | 2022 | |
| Arbor Pharmaceuticals, INC. | $20.40 | 2019 | |
| Scilex Pharmaceuticals INC. | $18.57 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ehum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.